Search the Newsreel

Barings BDC (BBDC) Q2 2026 Earnings Report - Results, Call & Slides

Should Value Investors Buy Barings BDC (BBDC) Stock?

Barings BDC (BBDC) is presented as a strong value stock due to its favorable Zacks Rank #2 (Buy) and Value grade of A. The article highlights BBDC's attractive P/E, P/B, and P/CF ratios compared to its industry averages, suggesting it is currently undervalued. Investors …

Barinthus Biotherapeutics plc Revenue Breakdown – NASDAQ:BRNS

Avoiding Lag: Real-Time Signals in (BBDC) Movement

This article provides a real-time analysis of Barings Bdc Inc. (NASDAQ: BBDC) movement, highlighting a near-term strong sentiment but a neutral mid and long-term outlook. AI-generated trading strategies are offered for different risk profiles, including position, momentum breakout, and risk hedging strategies. The analysis …

Barings BDC (BBDC) Q2 2023 Earnings Report - Results, Call & Slides

Barinthus Biotherapeutics (Nasdaq: BRNS) details Q2 loss, cash and Clywedog merger plan

Barinthus Biotherapeutics (BRNS) reported a Q2 2026 net loss of $10.6 million and a six-month net loss of $16.1 million, improvements over the prior year due to reduced R&D and administrative expenses. The company holds $59.6 million in cash, expected to fund operations for …

Barings BDC Inc (BBDC) Stock News Today

Earnings call transcript: Barings BDC tops Q2 2026 estimates as shares rise

Barings BDC (BBDC) surpassed Q2 2026 earnings and revenue estimates, reporting $0.28 EPS against a $0.25 forecast and $65.2 million in revenue versus an expected $60.88 million. The company covered its $0.26 quarterly dividend, maintained leverage within target, and saw its shares rise 2.26% …

Barings BDC Reports Strong Q2 Results, Increases Dividend

Barings BDC reported strong Q2 2026 results, with total investment income of $65.2 million and net investment income of $29.0 million, or $0.28 per share, exceeding its dividend. The company's investment portfolio grew to $2.46 billion, maintaining stable leverage, and its board declared a …

Barinthus Biotherapeut reports Q2 2026 net loss $10.6M, cash $59.6M; VTP-1000 MAD data due Q4 2026

Barinthus Biotherapeutics reported a Q2 2026 net loss of $10.6 million and held $59.6 million in cash. The company completed enrollment for the VTP-1000 Phase 1 AVALON trial's multiple ascending dose portion, with topline data expected in Q4 2026. A proposed combination with Clywedog …

Barinthus Biotherapeutics plc. 2026: Revenue ($9.78M), Net income ($10.58M), EPS ($0.26) — 10-Q Summary

Barinthus Biotherapeutics plc. (BRNS) reported a narrower comprehensive loss in the 2026 quarter, driven by cost reductions and pipeline reprioritization towards immunology and inflammation programs. The company also completed enrollment for a Phase 1 clinical trial and entered a merger agreement with Clywedog, with …

Barings BDC Inc 2026 Q2 - Results - Earnings Call Presentation (NYSE:BBDC) 2026-08-06

Barings BDC Inc (NYSE:BBDC) released its Q2 2026 earnings call presentation on August 6, 2026. The company reported an EPS of $0.28, beating estimates by $0.04, and revenue of $65.20M, exceeding expectations by $5.10M despite a 12.36% year-over-year decrease. This presentation was published in …

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

Barinthus Bio announced its second quarter 2026 financial results and provided updates on corporate developments, including the progressing proposed combination with Clywedog Therapeutics Inc. The company completed enrollment for the Phase 1 AVALON trial of VTP-1000 for celiac disease, with topline data expected in …

Earnings Flash (BBDC) Barings BDC, Inc. Reports Q2 Total Investment Income $65.2M, Vs. FactSet Est of $60.1M

Barings BDC, Inc. (BBDC) announced its Q2 earnings, reporting a total investment income of $65.2 million. This figure exceeded FactSet's estimate of $60.1 million, indicating stronger financial performance than anticipated.

Barings Bdc, Inc. to Issue Quarterly Dividend of $0.26 (NYSE:BBDC)

Barings Bdc, Inc. (NYSE:BBDC) announced a quarterly dividend of $0.26 per share, payable on September 9th to shareholders of record on September 2nd. This dividend represents an annualized yield of 12.4%, but the company's dividend payout ratio of 105.1% suggests it cannot cover the …

Barings BDC, Inc. Q2 2026: Revenue $65.2M, EPS $0.18— 10-Q Summary

Barings BDC, Inc. reported its Q2 2026 financial results, showing investment income of $65.2 million and a net increase in net assets from operations of $18.3 million, or $0.18 per share. These figures represent a modest decline compared to the previous year, attributed to …

Barings BDC: Q2 Earnings Snapshot

BBDC: NAV per share fell to $10.94, with strong income and a stable dividend maintained

Barings BDC (BBDC) reported a decline in NAV per share to $10.94 due to unrealized depreciation, yet maintained a strong net investment income of $0.28 per share. The portfolio yield remained robust at 10.2%, and the company successfully upheld its regular dividend for the …

Barings BDC made 21 new investments totaling $172.1M in Q2

Barings BDC, Inc. (BBDC) reported its second quarter 2026 financial results, announcing a quarterly cash dividend of $0.26 per share. The company generated strong earnings, over-earning its dividend, and made 21 new portfolio investments totaling $172.1 million, alongside $90.0 million in existing portfolio companies. …

Barings Bdc (NYSE:BBDC) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Barings Bdc (BBDC) Earnings Date and Reports 2026

Barings BDC Inc (BBDC) Financial Health: Profitability & Balance Sheet Analysis

Barings BDC Inc (BBDC) currently holds a strong financial score of 9.20, ranking first in its industry. Despite this robust standing, the company reported a year-over-year decrease in its latest quarterly revenue by 22.61% to $54.66 million, and net profit declined by 38.63%. The …

BBDC5750362 Bond Profile — Key Metrics

This article provides key metrics and profile information for the BBDC5750362 bond issued by Barings BDC, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, face value, and minimum denomination. Additionally, it offers a brief description of Barings BDC, Inc. …

Barings Bdc (BBDC) Expected to Announce Earnings on Wednesday

Barings BDC (BBDC) is set to announce its Q2 2026 earnings on Wednesday, August 5th, with analysts anticipating earnings of $0.25 per share and revenue of $60.88 million. The company's previous quarter met earnings expectations but missed revenue estimates. BBDC recently traded at $8.39, …

Discipline and Rules-Based Execution in BBDC Response

This article provides an in-depth analysis of Barings Bdc Inc. (NASDAQ: BBDC), highlighting a neutral sentiment across all time horizons. It details institutional trading strategies, including long, breakout, and risk hedging options, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis …

BBDC6170076 Bond Risk Profile

This page provides a bond risk profile for BBDC6170076, issued by Barings BDC, Inc. with a 5.2% coupon and maturing on 15-SEP-2028. It highlights key metrics for assessing credit risk, including security level and issuer rating. The platform also offers access to exclusive analyst …

Barinthus Biotherapeutics PLC (BRNS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Barinthus Biotherapeutics PLC (BRNS), noting its current score of 1.98, ranking 247 out of 386 in the Biotechnology & Medical Research industry. The company's beta value is -0.39, indicating it tends to underperform in rising markets but …

Barinthus Biotherapeutics PLC (BRNS) Institutional Confidence

Barinthus Biotherapeutics PLC (BRNS) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion decreased by 10.63% quarter-over-quarter to 40.87%. James Simons is the largest institutional shareholder, holding 0.37% of …

Barinthus Biotherapeutics PLC (BRNS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Barinthus Biotherapeutics PLC's (BRNS) dividend history and stock splits. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information for BRNS.

Barings BDC, Inc. Revenue Breakdown – NYSE:BBDC

Barings BDC, Inc. (BBDC) generated `279.21 M` USD in revenue last year, with its Lending and Investment segment contributing `256.48 M` USD. The United States was the primary geographical contributor, also accounting for `256.48 M` USD of the company's revenue.

TradingKey

This article provides a detailed quarterly and annual cash flow statement for Barinthus Biotherapeutics PLC (BRNS), covering operating, investing, and financing activities from FY2020Q1 to FY2026Q1. It includes key financial figures such as net income, changes in working capital, capital expenditures, and free cash …

Barinthus Biotherapeutics plc Sponsored ADR Revenue Breakdown – GETTEX:2AB

This page provides financial information for Barinthus Biotherapeutics plc Sponsored ADR (2AB) on Gettex, indicating no current trading activity. It lists various financial data points like statements, statistics, dividends, earnings, and segment performance. The content appears to be a stub or an informational page …

Barinthus Biotherapeutics plc (BRNS) stock price, news, quote and history

Barinthus Biotherapeutics plc (BRNS) is a biotechnology company focused on developing immunotherapies and vaccines. The article provides current stock price data, historical performance, key financial metrics, and analyst ratings, indicating a buy recommendation with a target price of $5.50. The company is developing treatments …